Alto Pharmacy vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Alto Pharmacy is a full-service digital pharmacy delivering prescriptions to patients with a tech-enabled experience that coordinates with providers and insurance.
About
Alto Pharmacy is a digital pharmacy company founded in 2015 that provides a tech-enabled prescription delivery experience for patients managing ongoing medications and specialty drugs. The company differentiates from traditional pharmacies through proactive care coordination, where pharmacy staff work with patients and prescribers to address insurance prior authorizations, copay assistance programs, and adherence support rather than requiring patients to navigate these barriers themselves. Alto serves both retail pharmacy customers and specialty pharmacy customers managing complex medications for conditions including fertility, oncology, HIV, and mental health. The company raised over $350M and delivers to patients in multiple major US metropolitan areas. Alto's platform integrates with electronic health record systems to receive prescriptions digitally and provides prescribers with real-time visibility into whether patients have filled their medications. The company has positioned its proactive, high-touch model as particularly valuable for specialty drugs where adherence, insurance navigation, and side effect management require more support than standard retail pharmacies provide. Alto Pharmacy serves as an alternative to incumbent pharmacy benefit managers for employers and health plans that want better specialty pharmacy management.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.